Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The Congress Scientific Watch provides ESMO Members with fresh comments and analysis from selected abstracts presented during major international Oncology meetings.
Login and start reading, or Join ESMO - All articles are Open Access after 6 months.
From ESMO Breast Cancer 2022:
Preliminary phase Ib/II trial results suggest that first-line treatment with datopotamab deruxtecan plus durvalumab is active against locally advanced and metastatic triple-negative breast cancer
From ESMO Breast Cancer 2022:
Trastuzumab deruxtecan may help control intracranial metastases in patients with HER2-positive breast cancer
From ESMO Breast Cancer 2022:
Patients recruited to the monarchE trial on the basis of a high clinicopathological risk of early breast cancer recurrence derive a significant invasive disease-free survival benefit from abemaciclib use
From ESMO Breast Cancer 2022:
A single dose of HER3-targeted antibody–drug conjugate induces a CelTIL response in treatment-naïve early-stage hormone receptor-positive, HER2-negative breast cancer
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
